
    
      This study is designed to assess the safety and immunogenicity of DAPTACEL® vaccine
      administered at 4 to 6 years of age according to the US standard of care. The study
      population consists of PENTACEL™-primed subjects from Aventis Pasteur's pivotal studies
      494-01 and 494-03. These children will receive DAPTACEL® vaccine as a 5th dose immunization
      between 4 to 6 years of age.
    
  